CRP and systemic lupus erythematosus: We propose that the beneficial effect of transgenically expressed human CRP in EAE, and perhaps other T cell-mediated diseases like lupus and collagen-induced arthritis (26–37), is achieved via its capacity to inhibit DC development and function, thereby diminishing the stimulation of pathogenic T cells.